Cannabidiol for Health & Longevity - Quick Reference Sheet

Cannabidiol for Health & Longevity

Created on 06/13/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A non-intoxicating cannabis compound with one well-proven use: cutting seizures in rare severe childhood epilepsy. For everyday anxiety the signal is moderately encouraging but built on small studies; for pain and sleep it is weaker and mixed. Low doses are well tolerated; main concerns are liver enzyme changes at high doses and raising blood levels of other medicines. (Full Review)

Protocol

Standard protocol
10–25 mg once or twice daily
Titrate up over weeks; commonly 25–75 mg/day for anxiety or sleep. Anxiety trials used 300–600 mg single doses.
Administration with food
Take with a fatty meal
Markedly increases absorption and blood levels; dose consistently relative to meals for predictability.
Dosing schedule
Once- or twice-daily
Twice-daily split dosing keeps levels stable; long half-life (~14–60 h) makes once-daily feasible. Evening for sleep, morning for daytime anxiety.
Time to effect
Anxiety
1–2 hours
Acute effects felt within 1–2 hours of an oral dose.
Sleep, pain, inflammation
Days to weeks
Steady-state effects take days to a few weeks of consistent dosing to assess.

Benefits

Contraindications
  • Significant liver disease
  • Pregnancy or breastfeeding
  • Narrow-therapeutic-index drugs (anticoagulation, transplant immunosuppression)
  • Children except under specialist supervision
Key Interactions
  • Prescription drugs metabolized by CYP3A4, CYP2C19, CYP2C9 (warfarin, valproate, clobazam, tacrolimus, sirolimus, some antidepressants and antipsychotics)
  • OTC sedating antihistamines (diphenhydramine) and CNS depressants
  • Supplements via the same liver enzymes; grapefruit-derived supplements; St. John's wort
  • Sedating or calming supplements (melatonin, valerian, kava, magnesium, 5-HTP); anticoagulant supplements (high-dose fish oil, vitamin E, ginkgo)
  • Alcohol; concurrent THC

Risk & Side Effects

  • High: Liver enzyme elevation and drug-induced liver injury; sedation and somnolence; gastrointestinal effects
  • Medium: Drug interactions causing adverse events
  • Low: Reduced blood pressure and heart rate changes; product contamination and mislabeling
  • Speculative: Effects on male fertility; long-term and developmental risks

Monitoring

Marker Target Why
ALT (alanine aminotransferase) < 25 U/L (men), < 22 U/L (women) Detects CBD-related liver stress
AST (aspartate aminotransferase) < 25 U/L Confirms liver injury alongside ALT
Bilirubin (total) < 1.0 mg/dL Flags more significant liver injury when raised with enzymes
INR (if on warfarin) Per anticoagulation target (typically 2.0–3.0) Detects CBD-driven increase in bleeding risk
Blood pressure < 120/80 mmHg Tracks CBD's modest blood-pressure-lowering effect

Cadence: Baseline, then around 4–8 weeks after starting or a dose increase, and thereafter every 6–12 months for sustained use (more frequently with high doses or interacting drugs).

Qualitative Assessment

  • Anxiety levels and subjective sense of calm
  • Sleep quality and time to fall asleep
  • Pain intensity and interference with daily activities
  • Daytime drowsiness or fatigue
  • Gastrointestinal comfort (nausea, diarrhea)